Physician profile
Jordan Brecher
NPI 1376199893
$9,111.04
in general payments reported to CMS, 2019-2025
27 companies · $1,799 in 2025
The $1,799 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $514 · 2022: $1,192 · 2023: $1,393 · 2024: $4,213 · 2025: $1,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,961 · Travel and Lodging: $2,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,961.26 |
| Travel and Lodging | $2,443.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,600.85 | 2021-2025 | General - Therapies, Intracept, Wavewriter Alpha Prime 16 |
| Abbvie INC. | $905.27 | 2021-2025 | |
| Nevro Corp. | $516.38 | 2022-2024 | Senza |
| Medtronic, INC. | $435.28 | 2022-2024 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Scilex Pharmaceuticals INC. | $390.69 | 2021-2025 | Ztlido |
| Ibsa Pharma INC. | $188.65 | 2023-2025 | Licart, Tirosint, Tirosint |
| Si-Bone, INC. | $175.63 | 2024 | |
| Protega Pharmaceutials INC | $132.19 | 2023-2025 | Roxybond |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.72 | 2023-2025 | Relistor |
| Amgen INC. | $74.40 | 2021-2022 | |
| Pfizer INC. | $71.90 | 2023-2024 | |
| Averitas Pharma INC. | $62.55 | 2024 | Qutenza |
| Azurity Pharmaceuticals, INC. | $48.16 | 2023 | Horizant |
| Allergan, INC. | $41.31 | 2022 | |
| Collegium Pharmaceutical, INC. | $38.97 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $36.39 | 2021-2023 | Amyvid |
| Takeda Pharmaceuticals U.S.A., INC. | $34.29 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.92 | 2022 | |
| Nalu Medical, INC. | $31.70 | 2024 | Nalu Neurostimulation System |
| Idorsia Pharmaceuticals US INC | $29.05 | 2022-2023 | Quviviq |
| Saluda Medical Americas, INC. | $28.52 | 2024 | Evoke |
| Ge Healthcare | $24.79 | 2022 | |
| Valinor Pharma, LLC | $22.08 | 2025 | Movantik |
| Grt US Holding, INC. | $21.39 | 2021 | |
| Bioventus LLC | $20.69 | 2023 | Stimrouter Implantable Kit |
| Biohaven Pharmaceuticals, INC. | $16.59 | 2021 | |
| Curonix LLC | $14.68 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Brecher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.